

MARKET ESTIMATES & TREND ANALYSIS

# Alopecia Therapeutics Market

Market, by Treatment (Topical, Oral, Others)

Market, by Gender (Male, Female)

SAMPLE PAGES



GRAND VIEW RESEARCH

# ABOUT US

**G**RAND VIEW RESEARCH is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries including Healthcare, Technology, Chemicals, Materials, and Energy. With a deep-seated understanding of many business environments, Grand View Research provides strategic objective insights. We periodically update our market research studies to ensure our clients get the most recent, relevant, and valuable information. Grand View Research has a strong base of analysts and consultants from assorted areas of expertise. Our industry experience and ability to zero-in on the crux of any challenge gives you and your organization the ability to secure a competitive advantage.

Copyright © 2016 Grand View Research Inc., USA

All Rights Reserved. This document contains highly confidential information and is the sole property of Grand View Research. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Grand View Research.

## DOCUMENT GUIDE

### Market Research Services

[\(Click to  
navigate to the  
section\)](#)

- This section highlights pre and post sale services rendered by Grand View Research to the clients

### Report Sample

[\(Click to  
navigate to the  
section\)](#)

- This section of the report is designed to provide a model of the actual deliverable/report. This section is for representative purposes only and include excerpts from the original report.
- The first illustration is designed to provide clients with a general insight into the structure of a report

### Table of Contents

[\(Click to  
navigate to the  
section\)](#)

- Gain access to the table of contents of the actual report

## MARKET RESEARCH SERVICES

### Pre-sale Support

- Free Product Review Call With The Author
- 10% Free Customization
- Design an Exclusive Consumer Centric Study

### Post-Sale Support

- Free Analyst Access
- Post-Sale Customization Within The Study Scope
- Deliverable in Excel & PPT (Study Summary) on Request

### Bundle Design

- Talk to the Analyst to gain access to pertinent studies
- Avail Special Discounted Prices on Bundle Purchases
- Free Annual Study Update (For the first year)

## REPORT SAMPLE

### Market Outlook

- Includes market variables (drivers, restraints & opportunities)  
Impact analysis of these variables on market growth  
Use of analytical tools such as Porter's 5 Forces Analysis, PESTEL, Opportunity analysis, Ansoff's Matrix to represent the market dynamics

### Segment Outlook

- Multiple chapters encompassing market estimates, forecasts & CAGR of pertinent market segments (namely application, technology, end-use, product categories etc.)  
Associated product or market developments and associated trend analysis  
Regional and country level estimates and forecasts each segment

### Competitive Landscape

- Key business strategy analysis vis-a-vis R&D, sustainability etc.  
Company profiles of all major market participants analyzed using attributes such as company overview, financial performance, strategy undertakings & product portfolio

# Chapter 1 Methodology and Scope

---

## 1.1 Research Methodology

We have implemented a mix of primary and secondary research for our market estimate and forecast. Secondary research formed the initial phase of our study, where we conducted extensive data mining, referring to verified data sources such as independent studies, government and regulatory published material, technical journals, trade magazines paid data sources.

For forecasting, the following parameters were considered,

- Market drivers and restraints, along with their current and expected impact
- Technological scenario and expected developments
- End-use industry trends and dynamics
- Consumer behavior trends
- Disease prevalence pattern
- Healthcare spending, per capita healthcare expenditure
- Healthcare reforms and regulatory frameworks
- Export import policies

We assigned weights to these parameters and have quantified their market impact using weighted average analysis, to derive an expected market growth rate.

All our estimates and forecasts were verified through exhaustive primary research with Key Industry Participants (KIPs) which typically include,

- Market leading companies
- Healthcare practitioners

The key objectives of primary research are as follows,

- To validate our data in terms of accuracy and acceptability
- To gain an insight in to the current market and future expectations

## 1.2 Research Scope & Assumptions

- The report provides market value for base year 2015 and a yearly forecast to 2024 in terms of revenue (USD Million)

- Key industry dynamics, regulatory scenario, major technological trends and Delivery Mode markets are evaluated to understand their impact on demand for the forecast period. Growth rates are estimated using correlation, regression and time-series analysis.
- Inflation has not been accounted for while market estimation
- Numbers might not add up due to rounding off
- We have used a mixture of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics and trends for various end-uses
- All market estimates and industry analysis have been validated through exhaustive primary research with key industry participants and consumers.

### 1.3 List of Data Sources

List of **secondary** sources include but are not limited to:

- WHO
- NCBI
- American Hair Loss Association
- xx
- xx

List of **primary** sources include but are not limited to:

- xxxx
- xxxx
- xxxx

## Chapter 2 Executive Summary

## 2.1 Global Alopecia Therapeutics Market – Industry Snapshot & Key Buying Criteria

[illegible]

Source: WHO, U.S. CDC, FDA, NIH Journals, Investor Presentations, Primary Interviews, Grand View Research

The global alopecia therapeutics market is segmented into treatment, gender and region. As of 2015, this market held a share of USD 73.4 billion globally. The key factors attributed are the increasing prevalence of various chronic diseases such as arthritis, depression, PCOS, diabetes mellitus, hypertension, and cancer, easy access to scalp treatment, and the research & development of several alopecia treatment products. The increasing level of air and water



pollution changing lifestyles of people such as increasing consumption of alcohol, tobacco, and other related products, increasing stress levels, and the rapidly growing geriatric population are expected to boost the alopecia treatment market during the forecast period. The rising disposable incomes coupled with the rising celebrity culture and the increased emphasis being laid on visual appearance; are the factors that altogether contribute to the alopecia therapeutics market growth. Additionally, technological advancements in the product development of novel therapeutic options is one of the important drivers of the alopecia market.

The key market players of alopecia therapeutics include Cipla, Merck & Co., Johnson & Johnson, Lifes2good, Dr. Reddy's Laboratories, Sun Pharma, Kirkland Signature, Alpecin, Vitabiotics, and Phyto Ales Group

**TABLE 1 Global Alopecia Therapeutics Market by Treatment, 2013 – 2024 (USD Million)**

Treatment	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	CAGR (2016-24)
Oral Hair Loss Treatment	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%
Topical Hair Loss Treatment	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%
Injectables and Other Treatment Options	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%
Total	xx	xx	7343.0	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%

Source: WHO, U.S. CDC, FDA, NIH Journals, Investor Presentations, Primary Interviews, Grand View Research

As of 2015, the topical hair loss treatment held the largest share of the market accounting for USD xx million and the oral hair loss treatment is expected to witness lucrative growth of xx% over the forecast period.

**TABLE 2 Global Alopecia Therapeutics Market By Gender, 2013 – 2024 (USD Million)**

Gender	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	CAGR (2016-24)
Male	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%
Female	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%
Total	xx	xx	7343.0	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%

Source: WHO, U.S. CDC, FDA, NIH Journals, Investor Presentations, Primary Interviews, Grand View Research

In 2015, the female segment held the largest share of the market accounting for USD xx million and it is also expected to witness lucrative growth of xx% over the forecast period.

**TABLE 3 Global Alopecia Therapeutics Market by Region, 2013 – 2024 (USD Million)**

Region	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	CAGR 2016-24)
North America	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%
Europe	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%
Asia Pacific	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%
Latin America	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%
MEA	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%
Total	xx	xx	7343.0	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%


Source: WHO, U.S. CDC, FDA, Industry Journals, Annual Reports, Investor Presentations, Primary Interviews, Grand View Research

As of 2015, the North America held the largest share of the market accounting for USD xx million and it is also expected to witness lucrative growth of xx% over the forecast period.

## Chapter 3 Global Alopecia Therapeutics Industry Outlook

### 3.1 Market Segmentation

**FIG. 1** Global alopecia therapeutics: market segmentation




Source: WHO, U.S. CDC, FDA, NIH Journals, Investor Presentations, Primary Interviews, Grand View Research

We have estimated the global alopecia therapeutics market by segmenting it on three levels, which include treatment, gender and region. Treatment segments evaluated in this report include oral hair loss treatment, topical hair loss treatment and injectable & other treatment options. Gender segments evaluated are male and female. Besides, regional market estimates and forecasts for all the previously mentioned treatment and gender segments are presented in this report. Major regions included in this study are North America, Europe, Asia Pacific, Latin America and MEA.

### 3.2 Market Size and Growth Prospects

**FIG. 2** Global alopecia therapeutics market revenue, 2013 – 2024 (USD million)




Source: WHO, U.S. CDC, FDA, NIH Journals, Investor Presentations, Primary Interviews, Grand View Research

The global alopecia therapeutics market was valued at USD xx million in 2015 and is expected to grow at a CAGR of xx% over the forecast period.



### 3.4 Market Driver Analysis

**TABLE 4 Key Market Drivers Analysis**

Market Drivers	2015-18	2018-21	2021-24
	Impact		
Increasing global prevalence of alopecia			
Increasing global healthcare expenditure			
Increasing global prevalence of chronic diseases			
Technological advancements in alopecia treatment			

Source: WHO, U.S. CDC, FDA, NIH Journals, Investor Presentations, Primary Interviews, Grand View Research

#### 3.3.1 Increasing global prevalence of alopecia

The prevalence of alopecia is increasing at an alarming rate globally. In 2014 in the U.S., about 35 million men and 21 million women suffered from androgenetic alopecia and about 147 million people globally are expected to experience the same. As estimated by the American Hair Loss Association 95% of hair loss in men is androgenetic alopecia and about 1.7% of hair loss in 4.6 million affected people is alopecia areata. The occurrence of hair loss in men increases with the increase in the age. The International Society of Hair Restoration Surgery estimated that 40% of men at an age of 35 experiences hair loss, 65% at 60, 70% at 80 and 80% at an age of 85. According to NCBI, the incidence rate of alopecia for 2015 is as follows,

Country	No. of people under study	Incidence rate (%)
U.S.	530	2.1
India	808 patients, 572 controls	0.7
Singapore	219	3.8
Mexico	817	0.57

Source: WHO, U.S. CDC, FDA, NIH Journals, Investor Presentations, Primary Interviews, Grand View Research

Moreover, 73% of Asian men and women are estimated to suffer from hair loss. In 2012, in China, the prevalence rate for androgenetic alopecia was 19.9% in men and 0.1% in women and currently it is found to be 21% in males and 6% in females as suggested by NCBI. In the U.K. 15

per 10,000 people are estimated to suffer from alopecia areata and approximately 25 % of people are likely to develop alopecia totalis and alopecia universalis. Prevalence of alopecia in these countries is increasing due to the changing lifestyle of people such as increasing consumption of alcohol, tobacco and other associated products, changing food habits such as more consumption of junk food, the increasing level of stress and the increasing geriatric population. These factors have a positive impact on the global alopecia treatment market.

### 3.5 Market Restraint Analysis


TABLE 5 Key Market Drivers Analysis

Market Restraints	2015-18	2018-21	2021-24
	Impact		
Presence of alternative Hair Loss Therapies			

Source: WHO, U.S. CDC, FDA, NIH Journals, Investor Presentations, Primary Interviews, Grand View Research

### 3.6 Key Opportunities Prioritized

FIG. 4 Key opportunities prioritized



Source: Industry Journals, Annual Reports, Investor Presentations, Primary Interviews, Grand View Research

**Penetration** is defined as the maturity of the segment.

**Growth rate** is considered as the future projected CAGR till year 2024. These growth rates are comparative in nature, with the overall market growth rate as being the benchmark.








## Chapter 4 Global Alopecia Therapeutics Treatment Outlook

### 4.1 Global alopecia therapeutics market share by treatment, 2015 & 2024

Global alopecia therapeutics market based on treatment is classified as oral hair loss treatment, topical hair loss treatment and injectable & other treatment options. As of 2015, the topical hair loss segment held the largest share of the market accounting for USD xx million, whereas the oral hair loss treatment segment is expected to be the fastest growing at a CAGR of xx% during the forecast period.

**FIG. 7** Global alopecia therapeutics market share by treatment, 2015 & 2024



Source: WHO, U.S. CDC, FDA, NIH Journals, Investor Presentations, Primary Interviews, Grand View Research


### 4.2 Oral hair loss treatment

The oral hair loss treatment owes to be the fastest growing segment of the alopecia treatment market with a lucrative CAGR of about 5.0% over the forecast period. The key factors attributed are continuous innovations and introduction of new alopecia treatment therapeutic pipelines. Increasing prevalence of arthritis encourages the demand for its treatment, which results into hair loss. Thus, to prevent hair loss while on treatment for arthritis folic acid supplements are prescribed. Finasteride is the most abundantly used oral medication in men under the brand name

Propecia. DHT inhibitor prevents the conversion of testosterone to DHT, a hormone that initiates hair loss. The patent expiry of finasteride in 2013 triggered the entry of its bio generic forms. To treat alopecia in women oral contraceptives have proved to be more effective. As of now there is a vast range of oral medication available in the market such as Avacor, Spironolactone, Cimitidine, Cyproterone acetate, Ketokonazole, etc. Moreover, the introduction of new oral medications in the market is also accelerated. In 2015, FDA approved two drugs tofacitinib and ruxolitinib inhibiting Janus Kinase enzymes present in the hair follicles causing hair loss.

#### 4.2.1 Oral hair loss treatment market, 2013 – 2024 (USD Million)

**FIG. 8** Oral hair loss treatment market revenue, 2013 – 2024 (USD Million)



Source: WHO, U.S. CDC, FDA, NIH Journals, Investor Presentations, Primary Interviews, Grand View Research


The global oral hair loss treatment market was valued at USD xx million in 2015 and is expected to grow at a CAGR of xx% to reach USD xx million by 2024.

## Chapter 5 Global Alopecia Therapeutics Gender Outlook

### 5.1 Global alopecia therapeutics market share by gender, 2015 & 2024

Global alopecia therapeutics market based on gender is classified as male and female. As of 2015, the male segment held the largest share of the market accounting for USD xx million, and it is expected to be the fastest growing at a CAGR of xx% during the forecast period.

**FIG. 9** Global alopecia therapeutics market share by gender, 2015 & 2024




Source: WHO, U.S. CDC, FDA, NIH Journals, Investor Presentations, Primary Interviews, Grand View Research

### 5.2 Global male alopecia treatment market

American Hair Loss Association suggested that more than 95% of hair loss in men is androgenetic alopecia and about 50% of men tend to experience it at an average age of 50 according to the U.S. National Library of Medicine. Genetics and the male hormones namely, androgens are the major estimated reasons for androgenetic alopecia. The onset of this type of alopecia is noted after puberty when there is enough testosterone in men so as to get converted into DHT inhibitors that initially results into thinning of hair follicles and then eventually loss of hair. According to the studies carried out by NCBI prevalence of alopecia increases with the increase in age. The prevalence rate for age group of 40-55 years is 31% and it rises to 53% in an age group of 65-69 yrs. Alopecia areata, alopecia universalis, alopecia totalis and scarring alopecia are also

commonly noticed in men. The foremost drivers of this segment are the increasing geriatric population and increase in the smoking habits of men. The major brands of products used by men for hair loss treatment are Rogaine, Lipogaine, Kirkland Minoxidil, Infinite Growth and Nutrient.

### 5.2.1 Global male alopecia treatment market, 2013 – 2024 (USD Million)



Source: WHO, U.S. CDC, FDA, NIH Journals, Investor Presentations, Primary Interviews, Grand View Research


In 2015, the market value of this segment was USD xx million and it is expected to reach USD xx million by 2024 at a lucrative CAGR of xx%.

## Chapter 6 Global Alopecia Therapeutics Regional Outlook

### 6.1 Global alopecia therapeutics market share by region, 2015 & 2024

North America accounted for the largest share of the alopecia treatment market in 2015 owing to the high healthcare expenditure, technological advancements and the presence of organizations benefiting the market. Presence of favorable government initiatives and policies is also reinforcing the market in North America. However, Asia Pacific is expected to be the fastest growing region in alopecia treatment growing at a lucrative CAGR of about xx% over the forecast period as a consequence of high economic development in the region and the favorable government initiatives. Moreover, the increasing healthcare expenditure in emerging economies such as India and China also accounts for the growth of the market over this region.

**FIG. 11 Global alopecia therapeutics market share by region, 2015 & 2024**



Source: WHO, U.S. CDC, FDA, NIH Journals, Investor Presentations, Primary Interviews, Grand View Research


### 6.2 North America alopecia therapeutics market

North American region includes the U.S. and Canada markets. The increasing investment in R&D coupled with the augmented healthcare facilities is contributing to the largest share of this region over the market. The North American Hair Research Society and the American Hair Loss

Association conducts research on the treatment of alopecia by involving together scientist from different disciplinary. They also conduct meetings and programs periodically to discuss and spread awareness about hair loss and its associated treatments. The increasing number of the market players of alopecia treatment in this region is also expected to enhance the market growth over the forecast period.

#### 6.2.1 North America alopecia therapeutics market, 2013 – 2024, (USD Million)

**FIG. 12** North America alopecia therapeutics market revenue, 2013 – 2024 (USD Million)



Source: WHO, U.S. CDC, FDA, NIH Journals, Investor Presentations, Primary Interviews, Grand View Research

The North American alopecia therapeutics market was valued at USD xx million in 2015 and is expected to grow at a CAGR of xx% during the forecast period to reach USD xx million in 2024.



**TABLE 6 North America alopecia therapeutics market by treatment, 2013 – 2024 (USD Million)**

Region	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	CAGR (2016-24)
Oral hair loss treatment	745.7	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%
Topical hair loss treatment	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%
Others	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%
Total	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%

Source: WHO, U.S. CDC, FDA, NIH Journals, Investor Presentations, Primary Interviews, Grand View Research


**TABLE 7 North America alopecia therapeutics market by gender, 2013 – 2024 (USD Million)**

Gender	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	CAGR (2016-24)
Male	1019.0	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%
Female	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%
Total	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%

Source: WHO, U.S. CDC, FDA, NIH Journals, Investor Presentations, Primary Interviews, Grand View Research

#### 6.2.1.1 U.S. alopecia therapeutics market revenue, 2013 – 2024, (USD Million)

The U.S. dominated the overall North America market in 2015, owing to the increasing prevalence of androgenetic alopecia and alopecia areata accompanied with the rising healthcare expenditure. The incidence rate of androgenetic alopecia in 2014 was noted to be 35 million in men and 21 million in women and the prevalence rate of alopecia areata was 1.7% of the 4.6 million affected people. According to the World Health Organization, the healthcare expenditure per capita of the U.S. in 2014 was USD 9403 and it was marked to be the highest amongst all other countries. Furthermore, the Affordable Care Act offers an easy and affordable access to healthcare insurance thereby benefiting the people and also increasing the healthcare expenditure per capita for the country.

**FIG. 13 U.S. alopecia therapeutics market revenue, 2013 – 2024 (USD Million)**

Source: WHO, U.S. CDC, FDA, NIH Journals, Investor Presentations, Primary Interviews, Grand View Research

The U.S. alopecia therapeutics market was valued at USD xx million in 2015 and is expected to grow at a CAGR of xx% during the forecast period, to reach USD xx million in 2024.

**TABLE 8 U.S. alopecia therapeutics market by treatment, 2013 – 2024, (USD Million)**

Treatment	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	CAGR (2016-24)
Oral Hair Loss Treatment	655.9	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%
Topical Hair Loss Treatment	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%
Injectable and other treatment options	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%
Total	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%

Source: WHO, U.S. CDC, FDA, NIH Journals, Investor Presentations, Primary Interviews, Grand View Research

**TABLE 9 U.S. alopecia therapeutics market by gender, 2013 – 2024, (USD Million)**

Treatment	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	CAGR (2016-24)
Male	898.2	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%
Female	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%
Total	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx%

Source: WHO, U.S. CDC, FDA, NIH Journals, Investor Presentations, Primary Interviews, Grand View Research

## Chapter 7 Competitive Landscape

### 7.1 Cipla

#### 7.1.1 Company Overview

Cipla is a global pharmaceutical manufacturer headquartered in India and established in 1935. The core competencies of Cipla are in product development, product registration, product distribution and development of drug delivery systems. The key locations of their business are India, South Africa, Europe and North America. The major business units of Cipla are API, respiratory and veterinary products. Apart from this, it also focuses on other areas like cardiovascular therapies, dermatology & cosmetology, women & children care, urology, HIV/AIDS, diabetics, etc. Cipla dermatology & cosmetology has a wide range of products to treat different types of skin infections, acne, aging and hair-loss. Their alopecia treatment market consists of several products like minoxidil solutions, gels, shampoos and capsules.

#### 7.1.2 Financial Performance

2014	2015
USD 1.42 Billion	USD 1.53 Billion

Note: Net sales of Cipla. Conversion rate (05/05/2016): 1 INR = 0.015 USD.

#### 7.1.3 Product Benchmarking

Product	Application
Tugain (Minoxidil solution and gels)	Promote hair growth
Fluocinolone acetonide, Ciclopirax (Shampoos)	Prevent hair loss, Increases the volume hair
Finpecia/finasteride (Capsules)	Nourishes the hair

#### 7.1.4 Strategic initiative

- In January 2016, Cipla announced that they have about 200 drugs under development, out of which 50 drugs have the potential to generate USD 30 billion.
- In December 2015, Cipla acquired two US-based companies InvaGen and Exelan with a key objective of expanding their business in the U.S. generic market.
- In October 2015, Cipla entered into a partnership with Serum Institute of India to supply vaccines (polio, diphtheria, tetanus, BCG (tuberculosis), hepatitis B, measles, mumps and rubella) to South Africa.
- In March 2015, Cipla launched a new generic drug sofosbuvir (Hepcvir) useful for the treatment of chronic hepatitis C.

**Note: The final report would include the profiles of the following companies:**

1. Cipla
2. Merck & Co.
3. Johnson & Johnson
4. Lifes2good
5. Dr. Reddy's Laboratories
6. Sun Pharma
7. Alpecin
8. Vitabiotics
9. Phyto Ales Groupe

**APPENDIX-1****Table of Contents****Chapter 1      Methodology and Scope**

- 1.1      Research Methodology
- 1.2      Research Scope & Assumptions
- 1.3      List of Data Sources

**Chapter 2      Executive Summary****Chapter 3      Alopecia Therapeutics Industry Outlook**

- 3.1      Market segmentation
- 3.2      Alopecia therapeutics market dynamics
- 3.3      Market driver analysis
- 3.4      Market restraint analysis
- 3.5      Key Opportunities Prioritized
- 3.6      Industry analysis – Porter's
- 3.7      Alopecia Therapeutics market PESTEL Analysis
- 3.8      Alopecia key triggering factors
  - 3.8.1 Gynecological factors
  - 3.8.2 Dermatological factors

**Chapter 4      Alopecia Therapeutics Treatment Outlook**

- 4.1      Alopecia Therapeutics market share by treatment, 2015 & 2024
- 4.2      Oral treatment
  - 4.2.1 Oral treatment market estimates and forecasts, 2013-2024 (USD Million)
- 4.3      Topical treatment
  - 4.3.1 Topical treatment market estimates and forecasts, 2013-2024 (USD Million)
- 4.4      Other treatment options

- 4.4.1 Injectables and other treatment options market estimates and forecasts, 2013-2024 (USD Million)

## Chapter 5 Alopecia Therapeutics Gender Outlook

- 5.1 Alopecia therapeutics market share by gender, 2015 & 2024
- 5.2 Male
  - 5.2.1 Male market estimates and forecasts, 2013-2024 (USD Million)
- 5.3 Female
  - 5.3.1 Female market estimates and forecasts, 2013-2024 (USD Million)

## Chapter 6 Alopecia Therapeutics Regional Outlook

- 6.1 Alopecia therapeutics market share, by region, 2015 & 2024
- 6.2 North America
  - 6.2.1 North America Alopecia therapeutics market estimates and forecasts, by treatment, 2013 – 2024 (USD Million)
    - 6.2.1.1 U.S. market estimates and forecasts
    - 6.2.1.2 Canadamarket estimates and forecasts
  - 6.2.2 North America Alopecia therapeutics market estimates and forecasts, by gender, 2013 – 2024 (USD Million)
    - 6.2.2.1 U.S. market estimates and forecasts
    - 6.2.2.2 Canadamarket estimates and forecasts
- 6.3 Europe
  - 6.3.1 Europe Alopecia therapeutics market estimates and forecasts, by treatment, 2013 – 2024 (USD Million)
    - 6.3.1.1 UK market estimates and forecasts
    - 6.3.1.2 Germanymarket estimates and forecasts
  - 6.3.2 Europe Alopecia therapeutics market estimates and forecasts, by gender, 2013 – 2024 (USD Million)
    - 6.3.2.1 UK market estimates and forecasts
    - 6.3.2.2 Germanymarket estimates and forecasts

## 6.4 Asia Pacific

### 6.4.1 Asia Pacific Alopecia therapeutics market estimates and forecasts, by treatment, 2013 – 2024 (USD Million)

#### 6.4.1.1 Japan market estimates and forecasts

#### 6.4.1.2 Chinamarket estimates and forecasts

### 6.4.2 Asia Pacific Alopecia therapeutics market estimates and forecasts, by gender, 2013 – 2024 (USD Million)

#### 6.4.2.1 Japan market estimates and forecasts

#### 6.4.2.2 Chinamarket estimates and forecasts

## 6.5 Latin America

### 6.5.1 Latin America Alopecia therapeutics market estimates and forecasts, by treatment, 2013 – 2024 (USD Million)

#### 6.5.1.1 Brazil market estimates and forecasts

#### 6.5.1.2 Mexicomarket estimates and forecasts

### 6.5.2 Latin America Alopecia therapeutics market estimates and forecasts, by gender, 2013 – 2024 (USD Million)

#### 6.5.2.1 Brazil market estimates and forecasts

#### 6.5.2.2 Mexicomarket estimates and forecasts

## 6.6 MEA

### 6.6.1 MEA Alopecia therapeutics market estimates and forecasts, by treatment, 2013 – 2024 (USD Million)

#### 6.6.1.1 South Africa market estimates and forecasts

### 6.6.2 MEA Alopecia therapeutics market estimates and forecasts, by gender, 2013 – 2024 (USD Million)

#### 6.6.2.1 South Africa market estimates and forecasts

## Chapter 7 Competitive Landscape

### 7.1 Cipla.

#### 7.1.1 Company Overview

- 7.1.2 Financial Performance
- 7.1.3 Product Benchmarking
- 7.1.4 Strategic Initiatives
- 7.2 Merck & Co.
  - 7.2.1 Company Overview
  - 7.2.2 Financial Performance
  - 7.2.3 Product Benchmarking
  - 7.2.4 Strategic Initiatives
- 7.3 Johnson & Johnson.
  - 7.3.1 Company Overview
  - 7.3.2 Financial Performance
  - 7.3.3 Product Benchmarking
  - 7.3.4 Strategic Initiatives
- 7.4 Lifes2good.
  - 7.4.1 Company Overview
  - 7.4.2 Financial Performance
  - 7.4.3 Product Benchmarking
  - 7.4.4 Strategic Initiatives
- 7.5 Dr. Reddy's Laboratories.
  - 7.5.1 Company Overview
  - 7.5.2 Financial Performance
  - 7.5.3 Product Benchmarking
  - 7.5.4 Strategic Initiatives
- 7.6 Sun Pharma.
  - 7.6.1 Company Overview
  - 7.6.2 Financial Performance



- 7.6.3 Product Benchmarking
- 7.6.4 Strategic Initiatives
- 7.7 Alpecin.
  - 7.7.1 Company Overview
  - 7.7.2 Financial Performance
  - 7.7.3 Product Benchmarking
  - 7.7.4 Strategic Initiatives
- 7.8 Vitabiotics.
  - 7.8.1 Company Overview
  - 7.8.2 Financial Performance
  - 7.8.3 Product Benchmarking
  - 7.8.4 Strategic Initiatives
- 7.9 Phyto Ales Groupe.
  - 7.9.1 Company Overview
  - 7.9.2 Financial Performance
  - 7.9.3 Product Benchmarking
  - 7.9.4 Strategic Initiatives

## **List of Tables**

TABLE 1	Alopecia therapeutics – Industry Summary & Critical Success Factors (CSFs)
TABLE 2	Alopecia therapeutics market, by treatment, 2013 – 2024 (USD million)
TABLE 3	Alopecia therapeutics market, by gender, 2013 – 2024 (USD million)
TABLE 4	Alopecia therapeutics market, by region, 2013 – 2024 (USD million)
TABLE 5	Alopecia therapeutics – Key market driver analysis
TABLE 6	Alopecia therapeutics– Key market restraint analysis
TABLE 7	North America alopecia therapeutics revenue, by treatment, 2013 – 2024 (USD million)
TABLE 8	North America alopecia therapeutics revenue, by gender, 2013 – 2024 (USD million)
TABLE 9	US alopecia therapeutics revenue, by treatment, 2013 – 2024 (USD million)
TABLE 10	US alopecia therapeutics revenue, by gender, 2013 – 2024 (USD million)
TABLE 11	Canada alopecia therapeutics revenue, by treatment, 2013 – 2024 (USD million)
TABLE 12	Canada alopecia therapeutics revenue, by gender, 2013 – 2024 (USD million)
TABLE 13	Europe alopecia therapeutics revenue, by treatment, 2013 – 2024 (USD million)
TABLE 14	Europe alopecia therapeutics revenue, by gender, 2013 – 2024 (USD million)
TABLE 15	UK alopecia therapeutics revenue, by treatment, 2013 – 2024 (USD million)
TABLE 16	UK alopecia therapeutics revenue, by gender, 2013 – 2024 (USD million)
TABLE 17	Germany alopecia therapeutics revenue, by treatment, 2013 – 2024 (USD million)
TABLE 18	Germany alopecia therapeutics revenue, by gender, 2013 – 2024 (USD million)
TABLE 19	Asia Pacific alopecia therapeutics revenue, by treatment, 2013 – 2024 (USD million)
TABLE 20	Asia Pacific alopecia therapeutics revenue, by gender, 2013 – 2024 (USD million)
TABLE 21	Japan alopecia therapeutics revenue, by treatment, 2013 – 2024 (USD million)

TABLE 22	Japan alopecia therapeutics revenue, by gender, 2013 – 2024 (USD million)
TABLE 23	China alopecia therapeutics revenue, by treatment, 2013 – 2024 (USD million)
TABLE 24	China alopecia therapeutics revenue, by gender, 2013 – 2024 (USD million)
TABLE 25	Latin America alopecia therapeutics revenue, by treatment, 2013 – 2024 (USD million)
TABLE 26	Latin America alopecia therapeutics revenue, by gender, 2013 – 2024 (USD million)
TABLE 27	Brazil alopecia therapeutics revenue, by treatment, 2013 – 2024 (USD million)
TABLE 28	Brazil alopecia therapeutics revenue, by gender, 2013 – 2024 (USD million)
TABLE 29	Mexico alopecia therapeutics revenue, by treatment, 2013 – 2024 (USD million)
TABLE 30	Mexico alopecia therapeutics revenue, by gender, 2013 – 2024 (USD million)
TABLE 31	MEA alopecia therapeutics revenue, by treatment, 2013 – 2024 (USD million)
TABLE 32	MEA alopecia therapeutics revenue, by gender, 2013 – 2024 (USD million)
TABLE 33	South Africa alopecia therapeutics revenue, by treatment, 2013 – 2024 (USD million)
TABLE 34	South Africa alopecia therapeutics revenue, by gender, 2013 – 2024 (USD million)

## **List of Figures**

FIG. 1	Alopecia Therapeutics: Market Segmentation
FIG. 2	Alopecia Therapeutics Market Revenue, 2013 – 2024 (USD million)
FIG. 3	Alopecia Therapeutics Market Dynamics
FIG. 4	Key Opportunities Prioritized
FIG. 5	Alopecia Therapeutics – Porter's Analysis
FIG. 6	Alopecia Therapeutics Market – PESTEL Analysis
FIG. 7	Alopecia Therapeutics revenue share by treatment, 2015 & 2024
FIG. 8	Oral treatment revenue, 2013-2024 (USD million)
FIG. 9	Topical treatment revenue, 2013-2024 (USD million)

- FIG.10 Other treatments revenue, 2013-2024 (USD million)
- FIG.11 Alopecia Therapeutics revenue share by gender, 2015 & 2024
- FIG.12 Male population revenue, 2013-2024 (USD million)
- FIG.13 Female population revenue, 2013-2024 (USD million)
- FIG.14 Alopecia Therapeutics revenue share by region, 2015 & 2024
- FIG.15 North America alopecia therapeutics revenue, 2013 – 2024 (USD million)
- FIG.16 U.S.alopecia therapeutics revenue, 2013 – 2024 (USD million)
- FIG.17 Canada alopecia therapeutics revenue, 2013 – 2024 (USD million)
- FIG.18 Europe alopecia therapeutics revenue, 2013 – 2024 (USD million)
- FIG.19 UK alopecia therapeutics revenue, 2013 – 2024 (USD million)
- FIG.20 Germany alopecia therapeutics revenue, 2013 – 2024 (USD million)
- FIG.21 Asia Pacific alopecia therapeutics revenue, 2013 – 2024 (USD million)
- FIG.22 Japan alopecia therapeutics revenue, 2013 – 2024 (USD million)
- FIG.23 China alopecia therapeutics revenue, 2013 – 2024 (USD million)
- FIG.24 Latin America alopecia therapeutics revenue, 2013 – 2024 (USD million)
- FIG.25 Brazil alopecia therapeutics revenue, 2013 – 2024 (USD million)
- FIG.26 Mexico alopecia therapeutics revenue, 2013 – 2024 (USD million)
- FIG.27 MEA alopecia therapeutics revenue, 2013 – 2024 (USD million)
- FIG.28 South Africa alopecia therapeutics revenue, 2013 – 2024 (USD million)

## Disclaimer

In response to request/orders received, Grand View Research provides strategic business/market analysis services to a select group of customers that are limited to publications containing valuable market information. The publication is solely for our customers' internal use. It is acknowledged by our customer, by placing the order that no part of this strategic market analysis service is for general publication or disclosure to third party.

Grand View Research doesn't make any warranty for the accuracy of the data as these are primarily based on interviews and therefore, liable for fluctuation. Also, Grand View Research doesn't take responsibility for incorrect information supplied by manufacturers or users.

Any resale, lending, disclosure or reproduction of this publication can only be made with prior written permission from Grand View Research. Transmission and/or reproduction of this document by any means or in any form (includes photocopying, mechanical, electronic, recording or otherwise) are prohibited without the permission of Grand View Research.

## Registered Office Address

Grand View Research, Inc.

28 2nd Street, Suite 3036

San Francisco, CA 94105

United States

Phone: 1-415-349-0058

Email: [sales@grandviewresearch.com](mailto:sales@grandviewresearch.com)